Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with ...

South Korea’s Alteogen (Kosdaq: 196170) has signed an exclusive licensing agreement with Japanese pharmaceutical company ...

Pfizer plans to invest $1 billion in China by 2030 to support innovation, diagnostics, and the biotech sector, aligning with ...

Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new ...

Viracta Therapeutics has announced a restructuring to focus on its lead oncology candidate, nana-val, targeting EBV-positive ...

AlloVir will merge with Kalaris Therapeutics in an all-stock transaction, with Kalaris shareholders holding a 75% stake in ...

Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on ...

GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...

A review has found that complexities and inefficiencies within the UK’s health data infrastructure are hindering the ...

US healthcare giant Johnson & Johnson today revealed it has submitted applications with the US Food and drug Administration ...

US generic drugmaker Viatris (Nasdaq: VTRS) announced robust financial results for the third quarter of 2024, driven by ...